The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice
The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice
Simple item page
Full item details
- creativework.keywords - en
- Fc-effector
- convalescent plasma
- ADCC
- COVID-19
- neutrophils
- macrophages
- SARS-CoV-2
- IgG
- IgM
- IgA
- dc.contributor.author
- Ullah, Irfan
- Beaudoin-Bussières, Guillaume
- Symmes, Kelly
- Cloutier, Marc
- Ducas, Eric
- Tauzin, Alexandra
- Laumaea, Annemarie
- Bégin, Philippe
- Mothes, Walther
- Kumar, Priti
- Bazin, Renée
- Finzi, Andrés
- Uchil, Pradeep D.
- dc.date.accessioned
- 2024-01-12T14:24:17Z
- dc.date.available
- 2024-01-12T14:24:17Z
- dc.date.issued
- 2022-06-12
- dc.description.abstract - en
- COVID-19 convalescent plasmas (CCPs) are chosen for plasma therapy based on neutralizing titers and anti-Spike immunoglobulin levels. However, specific CCP characteristics that promote SARS-CoV-2 control in recipients are complex and incompletely defined. Using an in vivo imaging approach, we demonstrate that CCPs with low neutralizing and high Fc-effector activity, in contrast to those with poor Fc-function, afford effective prophylaxis and therapy in K18-hACE2 mice lethally challenged with SARS-CoV-2-nLuc. Macrophages and neutrophils significantly contributed to CCP effects during therapy but to a reduced extent under prophylaxis. Both IgG and Ig(M+A) were required during therapy, but the IgG fraction alone was sufficient during prophylaxis. Finally, despite neutralizing poorly, SARS-CoV-2 Wuhan-elicited CCPs delayed Delta and Beta variants of concern (VOC)-induced mortality in mice illustrating the contribution of polyclonal Fc-effector functions in immunity against VOCs. Thus, in addition to neutralization, Fc-effector activity is a significant criterion for CCP selection for therapeutic applications.
- dc.identifier.citation
- Ullah I, Guillaume Beaudoin-Bussières, Symmes K, et al. The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice. bioRxiv (Cold Spring Harbor Laboratory). Published online June 12, 2022. doi:https://doi.org/10.1101/2022.06.10.495677
- dc.identifier.doi
- https://doi.org/10.1101/2022.06.10.495677
- dc.identifier.uri
- https://open-science.canada.ca/handle/123456789/1744
- dc.language.iso
- en
- dc.publisher
- Cold Spring Harbor Laboratory
- dc.relation.isversionof
- https://open-science.canada.ca/handle/123456789/1747
- dc.rights - en
- Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
- dc.rights - fr
- Creative Commons Attribution - Pas d'utilisation commerciale - Pas de modification 4.0 International (CC BY-NC-ND 4.0)
- dc.rights.openaccesslevel - en
- Green
- dc.rights.openaccesslevel - fr
- Vert
- dc.rights.uri - en
- https://creativecommons.org/licenses/by-nc-nd/4.0/
- dc.rights.uri - fr
- https://creativecommons.org/licenses/by-nc-nd/4.0/deed.fr
- dc.subject - en
- Health
- dc.subject - fr
- Santé
- dc.subject.en - en
- Health
- dc.subject.fr - fr
- Santé
- dc.title - en
- The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice
- dc.type - en
- Submitted manuscript
- dc.type - fr
- Manuscrit soumis
- local.article.journaltitle
- bioRxiv
- local.pagination
- 1-62
- local.peerreview - en
- No
- local.peerreview - fr
- Non
Download(s)
Original bundle
1 - 1 of 1
Name: ullah-fc-effector-function-covid-19-convalescent-plasma-contributes-treatment-efficacy-mice-preprint.pdf
Size: 4.19 MB
Format: PDF
Collection(s)